



25268

PATENT TRADEMARK OFFICE

#4

0300

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Weng et al.

Attorney Docket No. THRS0002

Serial No.: 09/696,076

Group Art Unit:

Filed: October 25, 2000

Examiner:

Title: USE OF FOCUSED ULTRASOUND FOR VASCULAR SEALING

INFORMATION DISCLOSURE STATEMENT

Bellevue, Washington 98004

January 10, 2001

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

Applicants are aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.

- ☒ 1. Copies of the listed patents, publications, and other information are enclosed for the Examiner's use.
- ☐ 2. Copies of the listed patents, publications, and other information were previously cited by or submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. § 120.
- ☐ 3. A concise explanation of the relevance of document I.D. No. _____ (which is not in the English language), as presently understood by the individual designated under 37 C.F.R. § 1.56(c) most knowledgeable about its content, is provided _____.
- ☒ 4. Pursuant to 37 C.F.R. § 1.97(b), this information disclosure statement is being filed within three months of the filing date of the national application, within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, or before the mailing date of a first Office Action on the merits.
- ☐ 5. Pursuant to 37 C.F.R. § 1.97(c), this information disclosure statement is being filed after the period set forth in 37 C.F.R. § 1.97(b) but before the mailing date of either a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311, and is accompanied by:
- a. _____ a certification as specified in 37 C.F.R. § 1.97(e); or
- b. _____ the fee set forth in 37 C.F.R. § 1.17(p). Check No. _____ in the amount of \$ _____ is enclosed.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

6. Pursuant to 37 C.F.R. § 1.97(d), this information disclosure statement is being filed after the mailing date of either:

a. _____ a final action under 37 C.F.R. § 1.113; or

b. _____ a notice of allowance under 37 C.F.R. § 1.311,

but before payment of the issue fee. The statement is accompanied by a certification as specified in 37 C.F.R. § 1.97(e), a petition requesting consideration of the information disclosure statement, and the petition fee set forth in 37 C.F.R. § 1.17(i)(1). Check No. _____ in the amount of \$____ is enclosed.

X 7. Please charge any additional fees or credit any overpayment to Deposit Account No. 01-1940. A copy of this sheet is enclosed.

Respectfully submitted,


Ron Anderson

Ronald M. Anderson
Registration No. 28,829

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on January 10, 2001.

Date: January 10, 2001

Michelle L. Brien



**INFORMATION CITED BY APPLICANT(S) THAT MAY BE MATERIAL TO THE
PROSECUTION OF THE SUBJECT APPLICATION**

Applicants: Weng et al. Attorney Docket No. THRS0002
Serial No.: 09/696,076 Group Art Unit:
Filed: October 25, 2000 Examiner:
Title: USE OF FOCUSED ULTRASOUND FOR VASCULAR SEALING

U.S. PATENT DOCUMENTS

*Examiner Initial	ID	Document No.	Date	Name	Class	Sub- Class
_____	US1	4,929,246	5/29/1990	Sinofsky	606	8
_____	US2	5,415,657	5/16/1995	Taymor-Luria	606	49
_____	US3	5,507,744	4/16/1996	Tay et al.	606	50
_____	US4	5,810,810	9/22/1998	Tay et al.	606	50
_____	US5	5,882,302	3/16/1999	Driscoll, Jr. et al.	600	371
_____	US6	5,964,782	10/12/1999	Lafontaine et al.	606	213
_____	US7	5,993,389	11/30/1999	Driscoll, Jr. et al.	600	371
_____	US8	6,083,159	7/4/2000	Driscoll, Jr. et al.	600	371

FOREIGN PATENT DOCUMENTS

NONE CITED

OTHER INFORMATION

NONE CITED

Examiner's Signature

Date

*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RMA:mlb
1/10/01